12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Company News  |  Deals

Pharmacyclics, J&J deal

Pharmacyclics partnered with Johnson & Johnson's Janssen Biotech Inc. unit to co-develop and co-commercialize Pharmacyclics' hematological cancer compound PCI-32765. Pharmacyclics will receive $150 million up front and is eligible for up...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >